Provided by Tiger Trade Technology Pte. Ltd.

Vertex Pharmaceuticals

505.64
+3.330.66%
Post-market: 505.800.1600+0.03%18:41 EDT
Volume:806.75K
Turnover:408.87M
Market Cap:128.29B
PE:29.43
High:511.51
Open:504.08
Low:503.94
Close:502.31
52wk High:560.25
52wk Low:400.86
Shares:253.72M
Float Shares:253.72M
Volume Ratio:0.81
T/O Rate:0.32%
Dividend:- -
Dividend Rate:- -
EPS(TTM):17.18
EPS(LYR):15.32
ROE:23.54%
ROA:11.93%
PB:6.34
PE(LYR):33.01

Loading ...

Analysts Offer Insights on Healthcare Companies: Quest Diagnostics (DGX), AnaptysBio (ANAB) and Vertex Pharmaceuticals (VRTX)

TIPRANKS
·
Sep 23

Vertex Top Pick Affirmed as Inaxaplin Progress Supports Pipeline Upside; $672 Price Target Reiterated

TIPRANKS
·
Sep 23

Vertex Pharmaceuticals Incorporated : Jefferies Raises Target Price to $640 from $633

THOMSON REUTERS
·
Sep 23

Vertex's Kidney Drug Success Sparks a 22% Surge for This Rival Biotech

Dow Jones
·
Sep 23

U.S. Stocks on the MOVE-Greenland Mines, GameStop, Shopify

Reuters
·
Sep 22

Truist sees ‘significant positive readthrough’ for Maze from Vertex data

TIPRANKS
·
Sep 22

Maze jumps 25% to $27.99 after Vertex kidney disease data

TIPRANKS
·
Sep 22

Vertex Pharmaceuticals Incorporated Says Inaxaplin Reduces UACR by -42.7% at Week 13 in AMKD with Modest Proteinuria

Reuters
·
Sep 22

Vertex Pharmaceuticals Reports Positive Results for Inaxaplin Kidney Disease Trial

MT Newswires Live
·
Sep 22

Vertex Pharmaceuticals announces positive results from Phase 2b inaxaplin study

TIPRANKS
·
Sep 22

Vertex Says Phase 2b Amplified Study Shows Inaxaplin Cuts Proteinuria in APOL1-Mediated Kidney Disease Patients with Modest Proteinuria

Reuters
·
Sep 22

Vertex Pharmaceuticals Incorporated - Inaxaplin Reduces Uacr by -42.7% at Week 13 in Amkd with Modest Proteinuria

THOMSON REUTERS
·
Sep 22

Vertex Pharmaceuticals Incorporated - Inaxaplin Generally Safe and Well Tolerated in Both Amkd Cohorts

THOMSON REUTERS
·
Sep 22

Vertex Announces Positive Results from Phase 2B Amplified Study of Inaxaplin in Additional Populations of People with Apol1-Mediated Kidney Disease (Amkd) and Completion of Enrollment in the Phase 2/3 Amplitude Trial

THOMSON REUTERS
·
Sep 22

Vertex Pharmaceuticals Incorporated : Leerink Partners Resumes Coverage with Outperform Rating; Target Price $594

THOMSON REUTERS
·
Sep 21

Correction to Vertex Material Listing Article on Sept. 17

Dow Jones
·
Sep 21

Vertex Pharmaceuticals Inc. Stock Underperforms Friday When Compared to Competitors

Dow Jones
·
Sep 19

Vertex wins approval for 24/7 underground operations at Reward Gold Mine

TIPRANKS
·
Sep 18

Vortex Energy Moves to Acquire Saskatchewan Meadows Project for Future Energy Storage Potential

TIPRANKS
·
Sep 18

Malaysia's Vertex Material Sets Sights on 2027 U.S. Listing

Dow Jones
·
Sep 17